The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This could be stratospheric then for the share price if it’s successful!!
RNS Number : 9835R
NetScientific PLC
10 November 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Provides Business Update and Reports Q3 2021 Financial Results
London, UK - 10 November 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced its financial results for the quarter ended September 30, 2021 ("the Period") and provided a business update on its conference call today.
PDS Highlights for the Period:
-- Achieved several milestones in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA(R) for recurrent and/or metastatic human papillomavirus (HPV)16-associated head and neck cancer. These milestones include:
o Achievement of the preliminary safety benchmark for the first 12 patients
o Completion of enrolment for the first stage of the checkpoint inhibitor naïve arm (1st line treatment of recurrent or metastatic head and neck cancer).
o Initiated enrolment of the second arm of the study addressing checkpoint inhibitor refractory patients (2nd line treatment of recurrent or metastatic head and neck cancer)
-- Completed a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI's proprietary T-cell receptor gamma alternate reading frame protein (TARP) tumour antigen for use in PDS0102.
o PDS0102 is being developed to treat prostate cancer, breast cancer and acute myeloid leukaemia or AML.
o PDS0102 has demonstrated powerful induction of TARP-specific killer T-cells in preclinical studies.
-- Entered agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia for use in the development of PDS0202, a novel Versamune(R) -based universal flu vaccine.
-- Announced temporary administrative suspension of enrolment into the NCI-led study of the PDS0101 triple combination. PDS Biotech continues to be in contact with the NCI. Treatment of already enrolled patients has continued without interruption.
-- Announced the hiring of Matthew Hill as Chief Financial Officer, who has more than 25 years of experience in finance and operational leadership roles for life sciences companies.
Third Quarter 2021 Financial Results
PDS Biotech reported a net loss of approximately $7.0 million, or $(0.24) per basic and diluted share, for the three months ended September 30, 2021, compared to a net loss of approximately $3.9 million, or $(0.21) per basic and diluted share, for the three months ended September 30, 2020.
Research and development expenses increased to approximately $3.7 million for the three months ended September 30, 2021 from approximately $2.1 million for the three months ended September 30, 2020. The increase of $1.6 million was primarily attributable to an increase of $0.7 mill
Xxxx://www.pro active investors.co.uk/companies/news/965388/netscientific-land-7-3mln-space-agency-contract-for-investee-company-sofant-technologies-965388.html
Barry we know the treatment works with no ill effects so we have a lot to be excited about!!
V O X M A R K E T S
https://www.**********.co.uk/articles/traders-cafe-with-zak-mir-bulletin-board-heroes-october-25-c98442d/
Name trade is spot on. The geology for Jade is identical to a successfully drilled well 8km away and in fact that well has spilled over to fill Jade
Art most of the money raised from the 6p placing was from institutional investors and high net worth investors. Both of these groups are highly likely and can afford to exercise their warrants
Augustus, I was thinking the same thing! It’s nowhere to be found
Feel free to stop contributing to this bb if you have no interest in investing. Close the door on your way out there’s a good chap!’
A buy of 612k went through after hours
Hi Paul, Don’t forget empyrean has a 10 million loan facility in the worst case scenario. Either way the drill bit we definitely be turning!!
PDSB is storming ahead!! :)
Depends on news flow and results - we should find out more next week
Jimzt I topped up late yesterday for the bargain price of 112p! Cheap as chips!!
TIDMNSCI
RNS Number : 9234L
NetScientific PLC
16 September 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
I nvestment in Martlet Capital Limited
London, UK - 16 September 2021 - NetScientific plc (AIM: NSCI), an active holding company in life sciences and sustainability technology investment, is pleased to announce an initial GBP1m investment in Martlet Capital Limited ("Martlet Capital"), which intends to acquire a portfolio of minority interests in the Cambridge high-tech cluster.
NetScientific's fully-owned subsidiary EMV Capital Limited ("EMV Capital") has co-led a first close of a GBP12.0m investment into Martlet Capital, which has yet to start trading, alongside leading private office Saranac Partners. The investment is expected to enable Martlet Capital to complete the acquisition of a portfolio of over 50 minority investments of Marshall of Cambridge Limited, the "Martlet Capital" trading name and the team managing the investments. The investments include companies in life science, healthcare, cleantech, sustainability, industrials and semi-conductors (the "portfolio companies"), many with co-investments by some of the leading Cambridge and UK investment groups.
Martlet Capital is targeting an eventual total raise of approximately GBP22m over the next 6 months, which would enable significant further investment into selected portfolio companies and new investment opportunities. Martlet Capital aims to become the leading investment house for early-stage Cambridge technology cluster companies.
NetScientific's initial investment in Martlet has resulted in an initial equity interest of 6.8%.Through its "capital light" approach, EMV Capital intends to introduce syndicated investment into Martlet from its investor network, so reducing its initial investment from GBP1.0m to GBP0.25m. Following completion of the targeted GBP22m raise and the syndication of NetScientific's initial investment, it is expected that the Group's direct investment in Martlet will fall to circa 1%, but it will retain a significant interest through its "capital under advisory".
As a result of its investment in Martlet, the Group, together with Saranac Partners and Martlet, intends to establish shortly a follow-on funding vehicle Cambridge Marquity Investments Limited ("Marquity"), which is expected to be 40% owned by the Group in return for a GBP100,000 investment. The Group expects to make future judicious investments through Marquity, targeting the more advanced portfolio companies, which show the requisite strong performance to add shareholder value and realise returns. Finally, the Group intends to provide a line of credit of up to GBP1m to Marquity, enabling it to operate quickly and decisively, and capitalise on emerging opportunities from Martlet Capital.
NetScientific CEO, Dr. Ilian Iliev, will join the Board of Martlet and intends to join the Board of Marquity as a Non-Executive Director.
Ilian Iliev noted: "This investment mar
Zombi at a guess I’d say it’s more likely to be China related - simply because Coro hasn’t moved in the same way
This is painful to listen to Richard reading!